Quantum Biopharma Ltd. Class B Subordinate Voting SharesQNTM
About: Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.
Employees: 8
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
34% more capital invested
Capital invested by funds: $192K [Q3] → $256K (+$64.4K) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.06% less ownership
Funds ownership: 3.7% [Q3] → 3.63% (-0.06%) [Q4]
25% less funds holding
Funds holding: 12 [Q3] → 9 (-3) [Q4]
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Research analyst outlook
We haven’t received any recent analyst ratings for QNTM.
Financial journalist opinion









